CFG
SEEL

Citizens Financial Group’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Citizens Financial Group’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8
Closed -$20.7K – 476
2022
Q4 		$20.7K Hold
8
– – ﹤0.01% 416
2022
Q3 		$31K Hold
8
– – ﹤0.01% 407
2022
Q2 		$21K Buy
8
+3
+60% +$7.81K ﹤0.01% 419
2022
Q1 		$17K Buy
+5
New +$21.5K ﹤0.01% 442

Other funds holding SEEL

GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citizens Financial Group's SEEL Position: Q1 2023 in Review

Citizens Financial Group sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2023, closing a stake of 8 shares — an estimated $20.7K sold.

Citizens Financial Group first reported a position in SEEL in Q1 2022 and held it in 4 quarters. The position peaked at $31K in Q3 2022. 60 funds tracked by Wall St. Rank hold SEEL as of Q1 2023.

  • Citizens Financial Group reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citizens Financial Group sold 8 Seelos Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $20.7K.
  • Citizens Financial Group first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • Citizens Financial Group's Seelos Therapeutics, Inc. Common Stock position peaked at $31K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Citizens Financial Group's 13F filing for Q1 2023, filed 10 May 2023.